BeOne

China's National Medical Products Administration (NMPA) has approved 19 innovative drugs this year, with 15 developed by domestic companies, highlighting the country's biotech boom. Notable examples include sonrotoclax, a cancer drug developed by BeOne for treating adult blood cancers.

China’s National Medical Products Administration (NMPA) approved 19 innovative drugs in 2024, with 15 developed by domestic companies, highlighting the country’s biotech growth. Notable approvals include sonrotoclax by BeOne for treating adult blood cancers, as the regulator streamlines its approval process.

BeOne wins FDA approval in lymphoma race, while Biotech's cell therapy boom expands beyond cancer and CREATE Medicines raises $122 million to advance its in vivo CAR-T for autoimmune disease. The Trump administration is searching for a new FDA commissioner. BeOne's approval marks a significant development in the treatment of lymphoma.